Our present novel study is the first in vitro study confirming the efficacy and therapeutic benefit of LDN for ME/CFS patients by characterising the underlying regulatory mechanisms of LDN treatment involving TRPM3 and the opioid receptor interaction in NK cells. This evidence concerns the gene TRPM3 and myalgic encephalomeyelitis/chronic fatigue syndrome.